Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Turn Biotechnologies General Information
Turn Bio is advancing pre-clinical research for multiple indications including dermatology and immunology applications. Their lead candidate TRN-001 for skin rejuvenation uses the eTurna platform, while other candidates for ophthalmology and immune cell rejuvenation are being developed with the recently acquired ARMMs technology. The company hopes to advance to clinical trials in 2023 as mentioned in earlier reports[8].
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Mountain View, California
United States
United States
Drug Pipeline
TRN-001
Pre-clinicalKey Partnerships
HanAll Biopharma, Astellas Venture Management, Daewoong Pharmaceuticals
Turn Biotechnologies Funding
No funding data available
To view Turn Biotechnologies's complete valuation and funding history, request access »